Laracit 100mg / 5ml. 500mg / 14ml Injection
PDF Leaflet Revision Date: 8 October 2004
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of acute leukaemias and high-risk non-Hodgkin lymphomas.
Dosage (summary)
3-6 mg/kg/day or 100-200 mg/mu00b2/day; administered IV or intrathecally.
Special Populations
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Contraindicated; teratogenic in animals.
Contraindications
- Hypersensitivity to cytarabine
- Drug-induced bone marrow suppression
Common side effects
- Anaemia
- Leucopenia
- Thrombocytopenia
- Nausea
- Vomiting
Counselling Points
- Monitor blood counts regularly
- Report signs of infection
- Avoid pregnancy during treatment
Serious warnings
- Bone marrow suppression
- Anaphylaxis risk
- Neurotoxicity after intrathecal use
Important Disclaimer
The Laracit 100mg / 5ml. 500mg / 14ml Injection professional information leaflet below is the property of Teva and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
